MedPath

Efficacy of Lactoferin in HPV Clearance

Phase 3
Recruiting
Conditions
virus clearance in HPV+ patients.
Cervical high risk human papillomavirus (HPV) DNA test positive
R87.810
Registration Number
IRCT20231004059608N1
Lead Sponsor
Pasture Institute of Iran
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
80
Inclusion Criteria

Age: 25 to 50 years
Gender: Female
Marital Status: Married/Single
HPV positive patients (genotypes 16, 18, 31, 33, 39, 45, and 52)
Normal pap smear
Low grade pathology / CIN1

Exclusion Criteria

Pregnant women
observation of internal/external warts
history of surgery
?alchohol consumption
AIDS (HIV+)
Drug use within 90 days
People with systemic immunosuppressive disorders
Patients who have received local or systemic treatment in the last three months.
Abnormal pap smear
High grade pathology
Cancer
Conization history
Suffering from chronic diseases (diabetes, fatty liver and metabolic diseases, etc.)
Having more than 3 sexual partners
Patients with a history of treatment with Eldara and similar drugs (local and systemic)
History of Allergy, sensitivity to medicine, Anaphylaxis shock

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HPV clearance in HPV+ after 6 months. Timepoint: 0-3-6 month. Method of measurement: hpv genotyping test.;Pap smear. Timepoint: 0-3-6 month. Method of measurement: cytology and pap smear.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath